Who are 18F-2-fluoro-2-deoxy-D-glucose's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Slow Infusion of Rubidium-82, Fludeoxyglucose F18, N-13 ammonia intravenous injection.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/18f-2-fluoro-2-deoxy-d-glucose.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

18F-2-fluoro-2-deoxy-D-glucose — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

18F-2-fluoro-2-deoxy-D-glucose (18F-2-fluoro-2-deoxy-D-glucose) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Positron emission tomography (PET) imaging agent. Area: Oncology, Neurology, Cardiology.

phase 3 Positron emission tomography (PET) imaging agent Glucose transporter (GLUT1) and hexokinase Oncology, Neurology, Cardiology Small molecule Live · refreshed every 30 min

Target snapshot

18F-2-fluoro-2-deoxy-D-glucose (18F-2-fluoro-2-deoxy-D-glucose) — Eastern Health, Canada. 18F-FDG is a glucose analog labeled with fluorine-18 that accumulates in metabolically active tissues and emits positrons for PET imaging detection.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
18F-2-fluoro-2-deoxy-D-glucose TARGET	18F-2-fluoro-2-deoxy-D-glucose	Eastern Health, Canada	phase 3	Positron emission tomography (PET) imaging agent	Glucose transporter (GLUT1) and hexokinase
Slow Infusion of Rubidium-82	Slow Infusion of Rubidium-82	Ochsner Health System	marketed	Positron emission tomography (PET) imaging agent	Na+/K+-ATPase pump (potassium analog)
Fludeoxyglucose F18	Fludeoxyglucose F18	National Heart, Lung, and Blood Institute (NHLBI)	marketed	Positron emission tomography (PET) imaging agent	Glucose metabolism / GLUT1 transporter
N-13 ammonia intravenous injection	N-13 ammonia intravenous injection	Centre hospitalier de l'Université de Montréal (CHUM)	marketed	Positron emission tomography (PET) imaging agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Positron emission tomography (PET) imaging agent class)

Centre hospitalier de l'Université de Montréal (CHUM) · 1 drug in this class
Eastern Health, Canada · 1 drug in this class
National Heart, Lung, and Blood Institute (NHLBI) · 1 drug in this class
Ochsner Health System · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). 18F-2-fluoro-2-deoxy-D-glucose — Competitive Intelligence Brief. https://druglandscape.com/ci/18f-2-fluoro-2-deoxy-d-glucose. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab